The strong correlation between BCR clonotype diversity and gene signature of activated CD8+ T cells, along with lower malignant keratinocyte burden in these BCR-diverse tissues, suggests a mechanism where B cell clonal diversification following PD-1 blockade activates T cells leading to tumor clearance. This evidence concerns the gene BCR and neoplasm.